Upon adagrasib treatment, the KRAS Y96D mutation was associated with sustained ERK and AKT activation in several in vitro models including MIA Pa-Ca2 (pancreatic cancer), KRAS G12C/Y96D NSCLC cells and the MGH1138-1 patient-derived model (104). This evidence concerns the gene KRAS and pancreatic neoplasm.